William Richard White
CIK 1778739 · Chief Financial Officer · last filed 2026-06-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AKRO price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
601 GATEWAY BOULEVARD, SUITE 350
SOUTH SAN FRANCISCO, CA 94080
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IRON | Director | 1,756 | $81.26 | $142.7K | -$2.96M | 14 | 2026-06-23 |
| Ventyx Biosciences, Inc. (VTYX) Delisted | Director | 7,027 | $13.99 | $98.3K | -$1.17M | 8 | 2026-03-04 |
| Akero Therapeutics, Inc. (AKRO) Delisted | Chief Financial Officer | 0 | $54.65 | $0 | -$14.99M | 41 | 2025-12-09 |
Recent Filings · Page 7 of 8
73 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-12-23 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | — | -$1.5K | EDGAR |
| 2021-12-20 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | — | -$48.1K | EDGAR |
| 2021-12-10 | Akero Therapeutics, Inc. (AKRO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-11-03 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | — | -$99.0K | EDGAR |
| 2021-10-05 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | — | -$97.8K | EDGAR |
| 2021-09-03 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | — | -$145.4K | EDGAR |
| 2021-08-04 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | — | -$66.7K | EDGAR |
| 2021-07-08 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | — | -$113.8K | EDGAR |
| 2021-05-04 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | — | -$98.9K | EDGAR |
| 2021-04-05 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | — | -$1.08M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.